Compare AANJANEYA LIFECARE with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS DIVIS LABORATORIES DR. DATSONS LABS/
DIVIS LABORATORIES
 
P/E (TTM) x -10.9 32.6 - View Chart
P/BV x 0.2 7.4 2.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   DIVIS LABORATORIES
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
DIVIS LABORATORIES
Mar-18
DR. DATSONS LABS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1261,142 11.0%   
Low Rs31533 5.8%   
Sales per share (Unadj.) Rs133.0146.6 90.7%  
Earnings per share (Unadj.) Rs0.233.0 0.5%  
Cash flow per share (Unadj.) Rs6.638.4 17.2%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs128.8222.8 57.8%  
Shares outstanding (eoy) m31.66265.47 11.9%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.65.7 10.3%   
Avg P/E ratio x516.125.3 2,036.0%  
P/CF ratio (eoy) x11.821.8 54.3%  
Price / Book Value ratio x0.63.8 16.2%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m2,477222,318 1.1%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m564,561 1.2%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m4,21138,915 10.8%  
Other income Rs m791,134 6.9%   
Total revenues Rs m4,28940,049 10.7%   
Gross profit Rs m56912,617 4.5%  
Depreciation Rs m2041,425 14.3%   
Interest Rs m43013 3,234.6%   
Profit before tax Rs m1312,313 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m63,543 0.2%   
Profit after tax Rs m58,770 0.1%  
Gross profit margin %13.532.4 41.7%  
Effective tax rate %48.028.8 166.9%   
Net profit margin %0.122.5 0.5%  
BALANCE SHEET DATA
Current assets Rs m6,85245,351 15.1%   
Current liabilities Rs m6,7116,507 103.1%   
Net working cap to sales %3.399.8 3.4%  
Current ratio x1.07.0 14.6%  
Inventory Days Days161127 127.0%  
Debtors Days Days31895 334.7%  
Net fixed assets Rs m3,67321,160 17.4%   
Share capital Rs m317531 59.6%   
"Free" reserves Rs m3,76158,625 6.4%   
Net worth Rs m4,07859,156 6.9%   
Long term debt Rs m1,6710-   
Total assets Rs m12,63367,832 18.6%  
Interest coverage x1.0926.8 0.1%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.30.6 58.1%   
Return on assets %3.412.9 26.6%  
Return on equity %0.114.8 0.8%  
Return on capital %7.720.8 36.8%  
Exports to sales %22.90-   
Imports to sales %14.321.8 65.6%   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m6028,485 7.1%   
Fx inflow Rs m96432,359 3.0%   
Fx outflow Rs m6079,042 6.7%   
Net fx Rs m35723,317 1.5%   
CASH FLOW
From Operations Rs m1,3457,759 17.3%  
From Investments Rs m-2,256-4,783 47.2%  
From Financial Activity Rs m-1,200-3,142 38.2%  
Net Cashflow Rs m-2,111-166 1,271.5%  

Share Holding

Indian Promoters % 4.5 52.0 8.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.8 -  
FIIs % 1.4 19.0 7.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 17.2 547.1%  
Shareholders   20,807 31,796 65.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  PLETHICO PHARMA  

Compare DR. DATSONS LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - SANOFI INDIA COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS